Smart data in the operating room, Zimmer Biomet’s ROSA Knee with OptimiZe targets more precise implants

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 12:09. Details in the imprint.

With ROSA Knee with OptimiZe, Zimmer Biomet puts a chunky white robot next to the operating table that quietly tracks every movement and spits out live data while the surgeon works on the knee. In the theater, screens glow, sensors blink, and the system continuously suggests how to fine-tune implant placement. For patients this remains invisible under anesthesia, but the promise is simple - a knee replacement that fits more naturally and feels more like their own joint in daily life.

How ROSA Knee with OptimiZe works

ROSA Knee with OptimiZe combines a robotic arm, infrared cameras and tracking markers that are fixed to the patient’s leg to map the knee in real time. The system records how ligaments behave when the surgeon bends and straightens the joint, then proposes an implant position based on that soft-tissue behavior rather than on X-rays alone.

The surgeon controls everything, but the robot helps hold cutting guides steady and keeps angles and depths within tight tolerances. Screens show a colorful model of the knee with numbers that update as bone is removed and trial implants are inserted, so the team sees immediately if the joint feels too tight in flexion or too loose in extension.

What this changes for patients

For patients the decisive moment comes much later, when they walk down the hallway with crutches for the first time after surgery. A well-balanced ROSA-assisted knee should feel smoother, with less of the “mechanical” sensation some people describe after classic replacements. It is also meant to reduce mid-flexion instability, that unsettling feeling of the joint wobbling when you stand up from a chair.

Surgeons can individualize the implant position more aggressively, for example by subtly rotating or shifting components to match the patient’s native anatomy instead of forcing every knee into the same textbook alignment. That is particularly relevant for active patients who hope to return to hiking, gardening or light sports without constantly being reminded of their implant.

Strengths and compromises in everyday use

From the hospital’s angle ROSA Knee with OptimiZe is a serious investment in hardware, software and training, so it usually appears first in larger centers that do many knee replacements per year. The workflow aims to be efficient, but the first cases often take longer as teams climb the learning curve. Once routines are set, procedure times can approach conventional surgery again.

Not every patient will notice a dramatic difference, and outcomes still depend heavily on the surgeon’s decisions and rehabilitation quality. A robot cannot fix poor indications or skipped physiotherapy. But many surgeons report more consistent radiographic alignment and soft-tissue balance, which over time should translate into fewer dissatisfied knee patients in their clinics.

Where ROSA Knee with OptimiZe fits in Zimmer Biomet’s portfolio

ROSA Knee with OptimiZe is part of a broader Zimmer Biomet ecosystem that ranges from classic knee and hip implants to smart sensorized devices and digital care platforms. The idea is that surgeons plan in software, execute with robotic assistance, then follow patients through connected apps and remote monitoring tools.

In this network ROSA acts as the centerpiece in the operating room, talking to planning software and feeding back data on how implants were actually placed. Over time this creates a growing dataset that Zimmer Biomet can mine to refine planning algorithms and to support research on what alignment strategies work best for different patient types.

Context for investors and the stock

ROSA Knee with OptimiZe plays into the global shift toward robotic and data-supported orthopedics, where hospitals weigh higher upfront costs against potentially more predictable outcomes and marketing appeal. For Zimmer Biomet, this kind of platform can help defend market share in core joints while opening doors to new service revenues around software and analytics.

Shares of Zimmer Biomet (US98956P1021) trade in New York on the NYSE in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.